AbbVie falls as J&J psoriasis pill raises competition risk

ReutersMar 18, 2026 2:54 PM

Shares of drugmaker AbbVie ABBV.N fall 3.3% to $212.67 in early trading

Brokerage BNP Paribas maintains AbbVie at "neutral", sets price target at $213

Brokerage says J&J’s FDA approval of once‑daily oral psoriasis drug Icotyde could compete with AbbVie’s Skyrizi, a key growth driver

Brokerage adds Skyrizi should remain well-positioned due to strong efficacy and 12‑week dosing after induction, supporting patient compliance

Brokerage says an oral option could expand the psoriasis market beyond current 30–40% penetration, leaving room for Skyrizi growth

Forecasts Skyrizi to grow 23% in FY26, representing a key growth driver for AbbVie, brokerage says

J&J JNJ.N is also testing Icotyde in arthritis and bowel diseases, which could ramp up future competition, BNP said

ABBV shares up ~29% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

Tesla Stock Drops 5%: Is Tesla’s Growth Story Breaking Down or a Long-Term Buying Opportunity?

TradingKey - Tesla is at a clear inflection point. As its stock price continues to retreat, deliveries fall short of expectations, and inventory pressures mount, the market has begun to reevaluate its growth thesis. Valuations previously anchored by high growth and long-term narratives are now facin

Nike Stock Falls Below 50 Dollars Is It Still a Good Investment?

TradingKey - For much of early 2026, Nike (NKE) was under significant selling pressure, resulting in an accelerated selloff following its fiscal Q3 report, which resulted in the stock price being pushed below $50.

SpaceX IPO Ignites Space Stocks, Which Stock Is Most Worth Investing In?

TradingKey - For SpaceX, the question is no longer whether to go public, but rather that it has already entered a stage of substantive progress.

Amazon Talks to Acquire Globalstar: Can $9 Billion Deal Challenge SpaceX Starlink?

TradingKey - During after-hours trading on April 1, 2026, shares of satellite communications company Globalstar (GSAT) surged 24%, with its market capitalization briefly approaching $9 billion. The rally was triggered by an exclusive report from the Financial Times stating that e-commerce giant Amaz

Helium’s 2026 Shock: Which Stocks are Most Affected

Most investors don’t spend much time thinking about helium. It’s the party-balloon gas… or at least that’s what most people think. But But behind the scenes, helium keeps a lot of high-end tech running - and supply has tightened fast lately.

Tradingkey

KeyAI

